symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
BXRX,0.2,2.007378,3051684,1835468,0,0.195-9.2,-0.027,"Baudax Bio, Inc.",USD,0001780097,US07160F2065,07160F206,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.baudaxbio.com,"Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.",Dr. Geraldine A. Henwood Ph.D.,Healthcare,US,9,484 395 2440,490 Lapp Road,Malvern,PA,19355,28.7351,29.9151,https://financialmodelingprep.com/image-stock/BXRX.png,2019-11-14,True,False,True,False,False
